Disclosed are halo substituted derivative compounds of sobetirome with improved pharmacological characteristics relative to sobetirome, pharmaceutical compositions that include those compounds and methods of treating diseases such as neurodegenerative disorders using those pharmaceutical compositions.

Disclosed are halo substituted derivative compounds of sobetirome with improved pharmacological characteristics relative to sobetirome, pharmaceutical compositions that include those compounds and methods of treating diseases such as neurodegenerative disorders using those pharmaceutical compositions.

Disclosed are halo substituted derivative compounds of sobetirome with improved pharmacological characteristics relative to sobetirome, pharmaceutical compositions that include those compounds and methods of treating diseases such as neurodegenerative disorders using those pharmaceutical compositions.

A method is provided for producing polyimides by polycondensation of previously produced stoichiometric salts from polycarboxylic acids or their polyanhydrides and polyamines by heating the salts for dehydration. In the method, a) an aqueous solution of a water-soluble stoichiometric salt is produced from polycarboxylic acid and polyamine; b) the aqueous solution undergoes a processing step; and c) the salt contained in the solution is simultaneously or subsequently polycondensed, by heating to form a polyimide.

A method is provided for producing polyimides by polycondensation of previously produced stoichiometric salts from polycarboxylic acids or their polyanhydrides and polyamines by heating the salts for dehydration. In the method, a) an aqueous solution of a water-soluble stoichiometric salt is produced from polycarboxylic acid and polyamine; b) the aqueous solution undergoes a processing step; and c) the salt contained in the solution is simultaneously or subsequently polycondensed, by heating to form a polyimide.

The present invention relates to polyhydroxylated benzophenone compounds useful in the treatment of neurodegenerative, neurological, psychiatric, and cognitive diseases, in particular those associated with a deficiency in HDAC1 deacetylase activity.

The present invention relates to polyhydroxylated benzophenone compounds useful in the treatment of neurodegenerative, neurological, psychiatric, and cognitive diseases, in particular those associated with a deficiency in HDAC1 deacetylase activity.

4-Arylbenzoyl benzoic acid esters, such as the ethylhexyl esters and amyl esters of 4-phenylbenzoyl benzoic acid, are described, which are liquid and show excellent solubility in acrylic or methacrylic monomers. Compounds of Formula 1, wherein R.sup.1, R.sup.2, and A are as defined herein, are disclosed. They are suitable as components for radical photoinitiator systems for UV-curable compositions. ##STR00001##

4-Arylbenzoyl benzoic acid esters, such as the ethylhexyl esters and amyl esters of 4-phenylbenzoyl benzoic acid, are described, which are liquid and show excellent solubility in acrylic or methacrylic monomers. Compounds of Formula 1, wherein R.sup.1, R.sup.2, and A are as defined herein, are disclosed. They are suitable as components for radical photoinitiator systems for UV-curable compositions. ##STR00001##

Disclosed are halo substituted derivative compounds of sobetirome with improved pharmacological characteristics relative to sobetirome, pharmaceutical compositions that include those compounds and methods of treating diseases such as neurodegenerative disorders using those pharmaceutical compositions.